Meta-analysis of serum non-ceruloplasmin copper in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 38, Issue 4, 2014, Pages 809-822

  Squitti, Rosanna ^a,b   Simonelli, Ilaria ^a,b   Ventriglia, Mariacarla ^a   Siotto, Mariacristina ^c   Pasqualetti, Patrizio ^a,b   Rembach, Alan ^d   Doecke, James ^e   Bush, Ashley I ^d  

^a IRCCS ISTITUTO CENTRO SAN GIOVANNI DI DIO FATEBENEFRATELLI   (Italy)

^b IRCCS SAN RAFFAELE PISANA   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e CSIRO   (Australia)

Author keywords

Alzheimer's disease; Ceruloplasmin; Copper; Metal; Plasma; Serum

Indexed keywords

CERULOPLASMIN; COPPER;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CALIBRATION; CERULOPLASMIN BLOOD LEVEL; CONTROLLED STUDY; COPPER BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); PRIORITY JOURNAL; QUALITY CONTROL; STOICHIOMETRY;

ALZHEIMER'S DISEASE; CERULOPLASMIN; COPPER; METAL; PLASMA; SERUM;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; CERULOPLASMIN; COPPER; HUMANS; UP-REGULATION;

EID: 84890532894     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131247     Document Type: Article

References (59)

1. Hoogenraad T (2001) Wilson's Disease. Intermed Medical Publishers, Amsterdam/Rotterdam.
2. Jacobs D, Oxley, DK, DeMott, WR (2002) Laboratory Test Handbook: Concise with Disease Index, 2nd ed. Lexi-Comp, Hudson (Cleveland), OH.
3. Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS (2005) Relationship between serum copper, ceruloplasmin, and non-ceruloplasmin-bound copper in routine clinical practice. Clin Chem 51, 1558-1559.
4. Bielli P, CalabreseL(2002) Structure to function relationships in ceruloplasmin: A 'moonlighting' protein. Cell Mol Life Sci 59, 1413-1427.
5. Bento I, Peixoto C, Zaitsev VN, Lindley PF (2007) Ceruloplasmin revisited: Structural and functional roles of various metal cation-binding sites. Acta Crystallogr D Biol Crystallogr 63, 240-248.
6. Lopez-Avila V, Sharpe O, Robinson WH (2006) Determination of ceruloplasmin in human serum by SEC-ICPMS. Anal Bioanal Chem 386, 180-187.
7. Walshe JM (2003)Wilson's disease: The importance of measuring serum caeruloplasmin non-immunologically. Ann Clin Biochem 40, 115-121.
8. Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS (2007) Copper:caeruloplasmin ratio. J Clin Pathol 60, 441-442.
9. Twomey PJ, Wierzbicki AS, House IM, Viljoen A, Reynolds TM (2007) Percentage non-caeruloplasmin bound copper. Clin Biochem 40, 749-750.
10. Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS (2006) Adjusting copper concentrations for caeruloplasmin levels in routine clinical practice. J Clin Pathol 59, 867-869.
11. Bucossi S, Ventriglia M, Panetta V, Salustri C, Pasqualetti P, Mariani S, Siotto M, Rossini PM, Squitti R (2011) Copper in Alzheimer's disease: A meta-analysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimers Dis 24, 175-185.
12. Ventriglia M, Bucossi S, Panetta V, Squitti R (2012) Copper in Alzheimer's disease: A meta-analysis of serum, plasma, and cerebrospinal fluid studies. J Alzheimers Dis 30, 981-984.
13. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 12, 189-198.
14. Agarwal R, Kushwaha SS, Tripathi CB, Singh N, Chhillar N (2008) Serum copper in Alzheimer's disease and vascular dementia. Indian J Clin Bioch 23, 369-374.
15. Arnal N, Cristalli DO, de Alaniz MJ, Marra CA (2010) Clinical utility of copper, ceruloplasmin, and metallothionein plasma determinations in human neurodegenerative patients and their first-degree relatives. Brain Res 1319, 118-130.
16. Brewer GJ (2009) The risks of copper toxicity contributing to cognitive decline in the aging population and to Alzheimer's disease. J Am Coll Nutr 28, 238-242.
17. Lopez N, Tormo C, De Blas I, Llinares I, Alom J (2013) Oxidative stress in Alzheimer's disease and mild cognitive impairment with high sensitivity and specificity. J Alzheimers Dis 33, 823-829.
18. Molaschi M, Ponzetto M, Bertacna B, Berrino E, Ferrario E (1996) Determination of selected trace elements in patients affected by dementia. Arch Gerontol Geriatr 22(Suppl 1), 39-42.
19. Rembach A, Doecke JD, Roberts BR, Watt AD, Faux NG, Volitakis I, Pertile KK, Rumble RL, Trounson BO, Fowler CJ, WilsonW, Ellis KA, Martins RN, Rowe CC, Villemagne VL, Ames D, Masters CL, group Ar, Bush AI (2013) Longitudinal analysis of serum copper and ceruloplasmin in Alzheimer's disease. J Alzheimers Dis 34, 171-182.
20. Sedighi B, Shafa MA, Shariati M (2006) A study of serum copper and ceruloplasmin in Alzheimer's disease in Kerman, Iran. Neurology Asia 11, 107-109.
21. Snaedal J, Kristinsson J, Gunnarsdottir S, Olafsdottir, Baldvinsson M, Johannesson T (1998) Copper, ceruloplasmin and superoxide dismutase in patients with Alzheimer's disease. A case-control study. Dement Geriatr Cogn Disord 9, 239-242.
22. Squitti R, Barbati G, Rossi L, Ventriglia M, Dal Forno G, Cesaretti S, Moffa F, Caridi I, Cassetta E, Pasqualetti P, Calabrese L, Lupoi D, Rossini PM (2006) Excess of nonceruloplasmin serum copper in AD correlates with MMSE, CSF [beta]-amyloid, and h-tau. Neurology 67, 76-82.
23. Squitti R, Ghidoni R, Scrascia F, Benussi L, Panetta V, Pasqualetti P, Moffa F, Bernardini S, Ventriglia M, Binetti G, Rossini PM (2011) Free copper distinguishes mild cognitive impairment subjects from healthy elderly individuals. J Alzheimers Dis 23, 239-248.
24. Squitti R, Pasqualetti P, Dal Forno G, Moffa F, Cassetta E, Lupoi D, Vernieri F, Rossi L, Baldassini M, Rossini PM (2005) Excess of serum copper not related to ceruloplasmin in Alzheimer disease. Neurology 64, 1040-1046.
25. Squitti R, Pasqualetti P, Polimanti R, Salustri C, Moffa F, Cassetta E, Lupoi D, Ventriglia M, Cortesi M, Siotto M, Vernieri F, Rossini PM (2013) Metal-score as a potential non-invasive diagnostic test for Alzheimer's disease. Curr Alzheimer Res 10, 191-198.
26. Babiloni C, Squitti R, Del Percio C, Cassetta E, Ventriglia MC, Ferreri F, Tombini M, Frisoni G, Binetti G, Gurzi M, Salinari S, Zappasodi F, Rossini PM (2007) Free copper and resting temporal EEG rhythms correlate across healthy, mild cognitive impairment, and Alzheimer's disease subjects. Clin Neurophysiol 118, 1244-1260.
27. Zappasodi F, Salustri C, Babiloni C, Cassetta E, Del Percio C, Ercolani M, Rossini PM, Squitti R (2008) An observational study on the influence of the APOE-epsilon4 allele on the correlation between 'free' copper toxicosis and EEG activity in Alzheimer disease. Brain Res 1215, 183-189.
28. Capo CR, Arciello M, Squitti R, Cassetta E, Rossini PM, Calabrese L, Rossi L (2008) Features of ceruloplasmin in the cerebrospinal fluid of Alzheimer's disease patients. Biometals 21, 367-372.
29. Squitti R, Quattrocchi CC, Forno GD, Antuono P, Wekstein DR, Capo CR, Salustri C, Rossini PM (2007) Ceruloplasmin (2-D PAGE) pattern and copper content in serum and brain of Alzheimer disease patients. Biomark Insights 1, 205-213.
30. Squitti R, Quattrocchi CC, Salustri C, Rossini PM (2008) Ceruloplasmin fragmentation is implicated in 'free' copper deregulation of Alzheimer's disease. Prion 2, 23-27.
31. Basun H, Forssell LG, WetterbergL, WinbladB(1991) Metals and trace elements in plasma and cerebrospinal fluid in normal aging and Alzheimer's disease. J Neural Transm Park Dis Dement Sect 3, 231-258.
32. Baum L, Chan IH, Cheung SK, Goggins WB, Mok V, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HF, Zee BC, Cheng W, Chan MH, Szeto S, Lui V, Tsoh J, Bush AI, Lam CW, Kwok T (2010) Serum zinc is decreased in Alzheimer's disease and serum arsenic correlates positively with cognitive ability. Biometals 23, 173-179.
33. Bocca B, Forte G, Petrucci F, Pino A, Marchione F, Bomboi G, Senofonte O, Giubilei F, Alimonti A (2005) Monitoring of chemical elements and oxidative damage in patients affected by Alzheimer's disease. Ann Ist Super Sanita 41, 197-203.
34. Gonzalez C, Martin T, Cacho J, BrenasMT, Arroyo T, Garcia- Berrocal B, Navajo JA, Gonzalez-Buitrago JM (1999) Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. Eur J Clin Invest 29, 637-642.
35. Jeandel C, Nicolas MB, Dubois F, Nabet-Belleville F, Penin F, CunyG(1989) Lipid peroxidation and free radical scavengers in Alzheimer's disease. Gerontology 35, 275-282.
36. Kapaki E, Segditsa J, Zournas C, Xenos D, Papageorgiou C (1989) Determination of cerebrospinal fluid and serum lead levels in patients with amyotrophic lateral sclerosis and other neurological diseases. Experientia 45, 1108-1110.
37. Mattiello G, Gerotto M, Favarato M, Lazzri F, Gasparoni G, Gomirato L, Mazzolini G, Scarpa G, Zanaboni V, Pilone MG, Zatta PF (1993) Plasma microelement analysis from Alzheimer's and multi-infartual dementia patients. In Alzheimer's Diseases: Advances in Clinical and Basic Research, Corain B, Iqbal K, Nicolini M, Winblad B, Wisniewski H, Zatta P, eds. Wiley, Chichester, UK, pp. 267-272.
38. Molina JA, Jimenez-Jimenez FJ, Aguilar MV, Meseguer I, Mateos-Vega CJ, Gonzalez-Munoz MJ, de Bustos F, Porta J, Orti-Pareja M, Zurdo M, Barrios E, Martinez-ParaMC(1998) Cerebrospinal fluid levels of transition metals in patients with Alzheimer's disease. J Neural Transm 105, 479-488.
39. Ozcankaya R, Delibas N (2002) Malondialdehyde, superoxide dismutase, melatonin, iron, copper, and zinc blood concentrations in patients with Alzheimer disease: Crosssectional study. Croat Med J 43, 28-32.
40. Sevym S, Tamer UO, Doǧu I, Ozge O, A (2007) Can serum levels of copper and zinc distinguish Alzheimer's patients from normal subjects? J Neurol Sci (Turkish) 24, 197-205.
41. Shore D, Henkin RI, Nelson NR, Agarwal RP, Wyatt RJ (1984) Hair and serum copper, zinc, calcium, and magnesium concentrations in Alzheimer-type dementia. J AmGeriatr Soc 32, 892-895.
42. Smorgon C, Mari E, Atti AR, Dalla Nora E, Zamboni PF, Calzoni F, Passaro A, Fellin R (2004) Trace elements and cognitive impairment: An elderly cohort study. Arch Gerontol Geriatr Suppl, 393-402.
43. Squitti R, Lupoi D, Pasqualetti P, Dal Forno G, Vernieri F, Chiovenda P, Rossi L, Cortesi M, Cassetta E, Rossini PM (2002) Elevation of serum copper levels in Alzheimer's disease. Neurology 59, 1153-1161.
44. Vural H, Demirin H, Kara Y, Eren I, Delibas N (2010) Alterations of plasma magnesium, copper, zinc, iron and selenium concentrations and some related erythrocyte antioxidant enzyme activities in patients with Alzheimer's disease. J Trace Elem Med Biol 24, 169-173.
45. Sterne JA, Harbord R (2004) Funnel plot in meta-analysis. Stata Journal 4, 127-141.
46. Duval S, Tweedie R (2000) Trim and fill: A simple funnelplot- based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56, 455-463.
47. Ballantyne KN, van Oven M, Ralf A, Stoneking M, Mitchell RJ, van Oorschot RA, Kayser M (2012) mtDNA SNP multiplexes for efficient inference of matrilineal genetic ancestry within Oceania. Forensic Sci Int Genet 6, 425-436.
48. Squitti R (2012) Copper dysfunction in Alzheimer's disease: From meta-analysis of biochemical studies to newinsight into genetics. J Trace Elem Med Biol 26, 93-96.
49. Colabufo N, Squitti R (2012) Method and kit determination of free copper in serum. European Patent Office (EPO) (RO/EP), Patent number, PCT-SAFE Version 3.51.056.232 MT/FOP 20121001/0.20.5.19.
50. James SA, Volitakis I, Adlard PA, Duce JA, Masters CL, Cherny RA, Bush AI (2012) Elevated labile Cu is associated with oxidative pathology in Alzheimer disease. Free Radic Biol Med 52, 298-302.
51. Tang WH, Hartiala J, Fan Y, Wu Y, Stewart AF, Erdmann J, Kathiresan S, Roberts R, McPherson R, Allayee H, Hazen SL (2012) Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol 32, 2803-2812.
52. Higgins JP, Thompson SG, Deeks JJ, AltmanDG(2003) Measuring inconsistency in meta-analyses. BMJ 327, 557-560.
53. Giambattistelli F, Bucossi S, Salustri C, Panetta V, Mariani S, Siotto M, Ventriglia M, Vernieri F, Dell'acqua ML, Cassetta E, Rossini PM, Squitti R (2012) Effects of hemochromatosis and transferrin gene mutations on iron dyshomeostasis, liver dysfunction and on the risk of Alzheimer's disease. Neurobiol Aging 33, 1633-1641.
54. von Bernhardi R, Eugenin J (2012) Alzheimer's disease: Redox dysregulation as a common denominator for diverse pathogenic mechanisms. Antioxid Redox Signal 16, 974-1031.
55. Schrag M, Mueller C, Oyoyo U, Smith MA, Kirsch WM (2011) Iron, zinc and copper in the Alzheimer's disease brain: A quantitative meta-analysis. Some insight on the influence of citation bias on scientific opinion. Prog Neurobiol 94, 296-306.
56. Squitti R, Polimanti R (2013) Copper phenotype in Alzheimer's disease: Dissecting the pathway. Am J Neurodegener Dis 2, 46-56.
57. Kessler H, BayerTA, Bach D, Schneider-AxmannT, Supprian T, Herrmann W, Haber M, Multhaup G, Falkai P, Pajonk FG (2008) Intake of copper has no effect on cognition in patients with mild Alzheimer's disease: A pilot phase 2 clinical trial. J Neural Transm 115, 1181-1187.
58. Squitti R, Polimanti R, Bucossi S, Ventriglia M, Mariani S, Manfellotto D, Vernieri F, Cassetta E, Ursini F, Rossini PM (2013) Linkage disequilibrium and haplotype analysis of the ATP7B gene in Alzheimer's disease. Rejuvenation Res 16, 3-10.
59. Squitti R, Polimanti R, Siotto M, Bucossi S, Ventriglia M, Mariani S, Vernieri F, Scrascia F, Trotta L, Rossini PM (2013) ATP7B variants as modulators of copper dyshomeostasis in Alzheimer's disease. Neuromolecular Med 15, 515-522.